Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cullinan Oncology Inc. (CGEM : NSDQ)
 
 • Company Description   
Cullinan Management Inc. is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies for cancer patients. Cullinan Management Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 31

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.34 Daily Weekly Monthly
20 Day Moving Average: 1,120,068 shares
Shares Outstanding: 44.78 (millions)
Market Capitalization: $507.84 (millions)
Beta: 0.22
52 Week High: $37.66
52 Week Low: $7.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 7.28% 20.82%
12 Week -22.01% -14.27%
Year To Date -26.51% -14.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE MAIN STREET SUITE 520
-
CAMBRIDGE,MA 02142
USA
ph: 617-410-4650
fax: -
lroth@burnsmc.com http://www.cullinanoncology.com
 
 • General Corporate Information   
Officers
Nadim Ahmed - President; Chief Executive Officer
Jeffrey Trigilio - Chief Financial Officer
Thomas Ebeling - Director
Anne-Marie Martin - Director
Anthony Rosenberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 230031106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 44.78
Most Recent Split Date: (:1)
Beta: 0.22
Market Capitalization: $507.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $5.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $3.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 3.34
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.21
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 63.51%
Sales Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -%
ROE
03/31/22 - -17.75
12/31/21 - -14.58
09/30/21 - -15.80
ROA
03/31/22 - -17.32
12/31/21 - -14.30
09/30/21 - -15.42
Current Ratio
03/31/22 - 18.68
12/31/21 - 25.25
09/30/21 - 41.82
Quick Ratio
03/31/22 - -
12/31/21 - 25.25
09/30/21 - 41.82
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -356.25
09/30/21 - -329.33
Book Value
03/31/22 - 9.37
12/31/21 - 9.74
09/30/21 - 10.23
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©